Sunitinib: Ten years of successful clinical use and study in advanced renal cell carcinoma Academic Article uri icon


MeSH Major

  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Molecular Targeted Therapy


  • 2017;22:41-52 IMPLICATIONS FOR PRACTICE: Approved globally, sunitinib is established as a standard of care for first-line advanced renal cell carcinoma (RCC) therapy and, along with other targeted agents, has significantly altered the treatment landscape in RCC. Research with sunitinib that has sought to refine its role via patient selection and prognostic markers, improve dosing and adverse event management, and identify predictive efficacy biomarkers has contributed to the overall understanding and management of RCC. Key learnings regarding study design and data interpretation from the sunitinib studies and the sunitinib development program, in general, can be a model for the successful development of other agents.

publication date

  • January 2017



  • Academic Article



  • eng

PubMed Central ID

  • PMC5313263

Digital Object Identifier (DOI)

  • 10.1634/theoncologist.2016-0197

PubMed ID

  • 27807302

Additional Document Info

start page

  • 41

end page

  • 52


  • 22


  • 1